1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Lilly's Lung Cancer Drug Portrazza OK'd

 
• By Donna Young

The FDA on Nov. 24 gave Eli Lilly and Co. the go-ahead to market Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL) in combination with gemcitabine and cisplatin in the US for patients with metastatic squamous non-small-cell lung cancer (NSCLC) – the first biologic available as a first-line therapy for the very difficult-to-treat disease, which has only a five-year survival rate.

The FDA on Nov. 24 gave Eli Lilly and Co. the go-ahead to market Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL) in combination with gemcitabine and cisplatin in the US for patients with metastatic squamous non-small-cell lung cancer (NSCLC) – the first biologic available as a first-line therapy for the very difficult-to-treat disease, which has only a five-year survival rate.

"This is a complex disease and there is an urgent need for effective, first-line treatments," said Richard Gaynor, senior vice president, product development and medical affairs for Lilly Oncology. "The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

More from Therapy Areas

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.